Loading…
Pacira BioSciences, Inc. engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension for postsurgical pain management; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension indicated for the management of osteoarthritis and knee pain; and iovera system, a non-opioid handheld cryoanalgesia device used to deliver controlled doses of cold temperature to targeted nerves to produce neurolytic block that interrupts the pain-transmitting signals of a peripheral nerve. It also develops PCRX-201, a novel gene therapy vector platform enabling local administration of genetic medicines with the potential to treat large prevalent diseases like osteoarthritis. It has a development and commercialization, and supply agreement with Aratana Therapeutics, Inc. for NOCITA, a bupivacaine liposome injectable suspension product for use in animals. The company was formerly known as Pacira Pharmaceuticals, Inc. and changed its name to Pacira BioSciences, Inc. in April 2019. Pacira BioSciences, Inc. was incorporated in 2006 and is headquartered in Brisbane, California.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 10 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $726M | $123M | $7M | $137M | 1.0% | 3.6% | -107.1% |
| 2024 | $701M | $29M | $-100M | $179M | -12.8% | 3.9% | -337.3% |
| 2023 | $675M | $155M | $42M | $139M | 4.8% | 1.2% | 163.7% |
| 2022 | $667M | $140M | $16M | $115M | 2.1% | - | - |
| 2021 | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total Revenue | - | 666.82 | 674.98 | 700.97 | 726.41 |
| Operating Revenue | - | 666.82 | 674.98 | 700.97 | 726.41 |
| Cost Of Revenue | - | 199.30 | 184.67 | 170.43 | 149.75 |
| Gross Profit | - | 467.53 | 490.31 | 530.54 | 576.66 |
| Operating Expense | - | 407.50 | 402.63 | 440.67 | 557.47 |
| Research And Development | - | 84.80 | 76.26 | 81.58 | 117.31 |
| Selling General And Administration | - | 254.52 | 269.44 | 294.10 | 368.76 |
| Total Expenses | - | 606.80 | 587.30 | 611.09 | 707.22 |
| Operating Income | - | 60.02 | 87.68 | 89.87 | 19.19 |
| Total Operating Income As Reported | - | 60.02 | 87.68 | -73.37 | 19.19 |
| EBITDA | - | 140.38 | 154.58 | 29.12 | 122.50 |
| Normalized EBITDA | - | 140.38 | 171.51 | 184.84 | 123.49 |
| EBIT | - | 48.88 | 79.01 | -49.67 | 31.48 |
| Interest Income | - | 4.54 | 11.44 | 19.69 | 22.73 |
| Interest Expense | - | 35.58 | 17.31 | 13.44 | 14.61 |
| Net Interest Income | - | -35.43 | -8.86 | 3.12 | 5.29 |
| Other Non Operating Income Expenses | - | -11.29 | -0.19 | -0.37 | -6.62 |
| Other Income Expense | - | -11.29 | -17.11 | -156.10 | -7.60 |
| Interest Income Non Operating | - | 4.54 | 11.44 | 19.69 | 22.73 |
| Interest Expense Non Operating | - | 35.58 | 17.31 | 13.44 | 14.61 |
| Net Non Operating Interest Income Expense | - | -35.43 | -8.86 | 3.12 | 5.29 |
| Pretax Income | - | 13.30 | 61.70 | -63.11 | 16.87 |
| Tax Provision | - | -2.61 | 19.75 | 36.45 | 9.84 |
| Tax Rate For Calcs | - | 0 | 0 | 0 | 0 |
| Tax Effect Of Unusual Items | - | 0 | -5.42 | -32.70 | -0.21 |
| Net Income Continuous Operations | - | 15.91 | 41.96 | -99.56 | 7.03 |
| Net Income From Continuing And Discontinued Operation | - | 15.91 | 41.96 | -99.56 | 7.03 |
| Net Income From Continuing Operation Net Minority Interest | - | 15.91 | 41.96 | -99.56 | 7.03 |
| Net Income | - | 15.91 | 41.96 | -99.56 | 7.03 |
| Net Income Common Stockholders | - | 15.91 | 41.96 | -99.56 | 7.03 |
| Net Income Including Noncontrolling Interests | - | 15.91 | 41.96 | -99.56 | 7.03 |
| Normalized Income | - | 15.91 | 53.46 | 23.46 | 7.81 |
| Diluted NI Availto Com Stockholders | - | 15.91 | 46.07 | -99.56 | 7.03 |
| Basic Average Shares | - | 45.52 | 46.22 | 46.24 | 44.57 |
| Diluted Average Shares | - | 46.54 | 51.98 | 46.24 | 45.04 |
| Reconciled Depreciation | - | 91.50 | 75.57 | 78.78 | 91.02 |
| Reconciled Cost Of Revenue | - | 165.08 | 166.38 | 148.93 | 116.01 |
| Total Unusual Items | - | 0 | -16.93 | -155.72 | -0.98 |
| Total Unusual Items Excluding Goodwill | - | 0 | -16.93 | -155.72 | -0.98 |
| Special Income Charges | - | 0 | -16.93 | -155.72 | -0.98 |
| Other Special Charges | - | - | 16.93 | -7.52 | 0.98 |
| Impairment Of Capital Assets | - | 0 | 0 | 163.24 | 0 |
| Restructuring And Mergern Acquisition | - | 10.90 | -0.35 | 7.70 | 14.11 |
| Depreciation Amortization Depletion Income Statement | - | 57.29 | 57.29 | 57.29 | 57.29 |
| Depreciation And Amortization In Income Statement | - | 57.29 | 57.29 | 57.29 | 57.29 |
| General And Administrative Expense | - | 109.52 | 116.40 | 122.08 | 142.14 |
| Other Gand A | - | 73.99 | 82.74 | 87.23 | 100.28 |
| Salaries And Wages | - | 35.53 | 33.66 | 34.86 | 41.87 |
| Total Other Finance Cost | - | 4.40 | 3 | 3.13 | 2.84 |
| Other Operating Expenses | - | 10.90 | -0.35 | 7.70 | 14.11 |
| Selling And Marketing Expense | - | 145 | 153.04 | 172.02 | 226.62 |
| Average Dilution Earnings | - | 0 | 4.11 | 0 | 0 |
| Amortization | - | 57.29 | 57.29 | 57.29 | 57.29 |
| Amortization Of Intangibles Income Statement | - | 57.29 | 57.29 | 57.29 | 57.29 |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| Pacira BioSciences, Inc.this co. | PCRX | $892M | 126.89 | 1.29 | 1.0% | 8.75 |
| ARS Pharmaceuticals, Inc. | SPRY | $901M | -5.26 | 7.88 | -149.9% | -5.66 |
| Annexon, Inc. | ANNX | $893M | -4.32 | 4.22 | -97.7% | -3.54 |
| Xencor, Inc. | XNCR | $890M | - | 1.40 | -14.5% | - |
| Cullinan Therapeutics, Inc. | CGEM | $887M | -4.03 |
| - |
| - |
| - |
| - |
| - |
| - |
| 2.17 |
| -53.8% |
| -3.32 |
| MeiraGTx Holdings plc | MGTX | $886M | -7.76 | -152.99 | 1971.4% | -10.17 |
| Jade Biosciences, Inc. | JBIO | $876M | - | -18.71 | -38.3% | - |
| Certara, Inc. | CERT | $873M | -547.16 | 0.82 | -0.2% | 9.65 |
| Talkspace, Inc. | TALK | $871M | 111.78 | 7.44 | 6.7% | 129.10 |
| Peer Median | - | -4.79 | 1.79 | -26.4% | -3.43 | |